DENTSPLY SIRONA (NASDAQ:XRAY) Hits New 1-Year Low – Time to Sell?

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) shares hit a new 52-week low on Monday . The company traded as low as $9.85 and last traded at $9.8950, with a volume of 2869701 shares changing hands. The stock had previously closed at $10.07.

Analyst Upgrades and Downgrades

XRAY has been the topic of a number of research reports. Mizuho dropped their price objective on DENTSPLY SIRONA from $16.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Zacks Research upgraded DENTSPLY SIRONA from a “strong sell” rating to a “hold” rating in a report on Monday, March 2nd. Barrington Research increased their price objective on DENTSPLY SIRONA from $14.00 to $17.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Robert W. Baird increased their price objective on DENTSPLY SIRONA from $12.00 to $14.00 and gave the stock a “neutral” rating in a report on Friday, February 27th. Finally, Citigroup initiated coverage on DENTSPLY SIRONA in a report on Wednesday, April 15th. They issued a “sell” rating and a $10.00 price objective on the stock. Three research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $13.82.

DENTSPLY SIRONA Stock Up 1.0%

The business has a fifty day moving average of $11.59 and a 200 day moving average of $11.86. The stock has a market cap of $1.97 billion, a price-to-earnings ratio of -3.12, a P/E/G ratio of 1.17 and a beta of 0.93. The company has a debt-to-equity ratio of 1.52, a current ratio of 1.53 and a quick ratio of 0.98.

DENTSPLY SIRONA (NASDAQ:XRAY) last announced its quarterly earnings results on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing the consensus estimate of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. During the same quarter last year, the business earned $0.43 EPS. The company’s revenue for the quarter was up .1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. On average, equities analysts predict that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Gregory T. Lucier purchased 27,555 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were bought at an average price of $14.24 per share, with a total value of $392,383.20. Following the completion of the transaction, the director directly owned 27,555 shares in the company, valued at $392,383.20. This trade represents a ? increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director James D. Forbes purchased 5,000 shares of the company’s stock in a transaction dated Monday, March 9th. The stock was purchased at an average cost of $12.48 per share, for a total transaction of $62,400.00. Following the transaction, the director owned 10,000 shares of the company’s stock, valued at approximately $124,800. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last three months, insiders bought 70,000 shares of company stock worth $956,437. Insiders own 0.52% of the company’s stock.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of institutional investors have recently modified their holdings of XRAY. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of DENTSPLY SIRONA in the first quarter valued at approximately $26,000. Goldman Sachs Group Inc. boosted its position in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after acquiring an additional 2,172,343 shares during the period. Empowered Funds LLC boosted its position in shares of DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after acquiring an additional 1,320 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in shares of DENTSPLY SIRONA by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after acquiring an additional 41,579 shares during the period. Finally, Focus Partners Wealth boosted its position in shares of DENTSPLY SIRONA by 59.1% in the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after acquiring an additional 9,355 shares during the period. Institutional investors own 95.70% of the company’s stock.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.